PT-141 10mg
PT-141 10mg — for in vitro laboratory research use only.
Product Overview
PT-141 is a pharmaceutical-grade research compound supplied as a lyophilized powder. Each batch undergoes independent third-party testing with a Certificate of Analysis (COA) available on request.
Specifications
| CAS Number | 189691-06-3 |
| Molecular Formula | C50H68N14O10 |
| Molar Weight | ~1025.18 g/mol |
| Sequence | Cyclic heptapeptide (bremelanotide); alpha-MSH analog |
| Classification | Synthetic cyclic heptapeptide; melanocortin receptor (MC3R/MC4R) agonist |
| Appearance | White to off-white lyophilised powder (typical presentation) |
| Solubility | Soluble in sterile water or bacteriostatic water |
| Storage | Store lyophilised powder desiccated and protected from light at -20°C. Once reconstituted, store at 2-8°C for short-term use and avoid repeated freeze-thaw cycles. |
| Shelf Life | Typically stable for up to 24 months when stored lyophilised, desiccated, and protected from light at -20°C — confirm against the specific batch's Certificate of Analysis. |
Description & Mechanism of Action
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and an analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike peripherally-acting compounds such as PDE5 inhibitors, PT-141 acts centrally, binding melanocortin receptors MC3R and MC4R concentrated in the hypothalamus and limbic regions of the brain. Receptor binding activates a Gs-protein-coupled signalling cascade — adenylyl cyclase activation, rising intracellular cAMP, and secondary activation of phospholipase C (PLC) and ERK/MAPK pathways — which has been linked to increased dopaminergic neurotransmission in neural circuits associated with sexual motivation. PT-141 (as bremelanotide) received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women (brand name Vyleesi), and the receptor pharmacology summarised here reflects the basis for that approved indication.
Applications in Research
- Studying central melanocortin receptor (MC3R/MC4R) pharmacology
- Investigating cAMP/PLC/ERK signalling cascades in hypothalamic neurons
- Comparative research versus peripherally-acting compounds (e.g. PDE5 inhibitors)
- Dopaminergic neurotransmission and sexual-motivation circuit research
Handling, Reconstitution & Stability
- Handle as a hygroscopic powder; open vials and weigh under dry conditions where possible
- Reconstitute with sterile water or bacteriostatic water, adding solvent slowly down the side of the vial
- Swirl gently to dissolve — avoid vigorous shaking
- Filter-sterilise (e.g. 0.22 µm) immediately before use if required by your protocol
- Aliquot reconstituted solution and store at -20°C or below; avoid repeated freeze-thaw cycles
Precautions & Notes
- PT-141 (bremelanotide) holds FDA approval for a specific clinical indication (hypoactive sexual desire disorder, brand name Vyleesi); research use should not be conflated with that approved medical use
- Experimental effects are concentration-, duration-, and model-dependent
- Include appropriate experimental controls to distinguish specific from non-specific effects
- For laboratory research use only — not for human or veterinary use outside of an approved medical context
This product is supplied for in vitro research purposes only. It is not intended for human or animal administration, diagnostic use, or any other purpose. Handle in accordance with good laboratory practice guidelines.